MDS
Haematology · 2011–2023
4decisions
2medicines
2carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| lenalidomide Treatment of newly diagnosed multiple myeloma (as monotherapy, doublet therapy, or triplet therapy), progressive multiple myeloma, relapsed/refractory multiple… | Nov 2023 | Recommended | input received Rare Cancers Australia |
| decitabine + cedazuridine Treatment of myelodysplastic syndrome (MDS) and chronic myelomonocytic leukaemia (CMML) in high-risk patients. | Mar 2021 | Not recommended | input received Rare Cancers Australia |
| lenalidomide initial and continuing treatment of patients with myelodysplastic syndrome (MDS) defined as low or immediate-1 risk MDS associated with a deletion 5q… | Jul 2011 | Not recommended | unclear |
| lenalidomide initial and continuing treatment of a patient with myelodysplastic syndrome (MDS), defined as low or intermediate-1, who has a 5q cytogenetic abnormality and… | Mar 2011 | Not recommended | no section in document |
Who spoke
Rare Cancers Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.